Financings in Brief: Xomed Surgical Products
This article was originally published in The Gray Sheet
Xomed Surgical Products: Plans to go public via an initial public offering of 2.5 mil. shares at $19-21 each. The Jacksonville, Florida-based company has filed a registration statement with the Securities and Exchange Commission for the offering, which is "expected to occur in mid-October," the firm says. Xomed produces microendoscopy instruments, implantable devices, nerve monitoring systems and disposable fluid-control products for the earn, nose and throat surgery market. Alex. Brown & Sons and UBS Securities are underwriters for the offering...
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.